<p>Gyre Therapeutics, Inc.（纳斯达克代码：GYRE - 获取免费报告）周五股价下跌 4.7%。该股最低交易价为$9.63，最后交易价为$9.74。在午盘交易中，共成交 48,133 股，较平均交易量 80,171 股下降了 40%。该股此前收盘价为$10.22。</p>
<p>获取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>另外，Noble Financial 在 3 月 11 日（星期二）的一份研究报告中开始覆盖 Gyre Therapeutics 的股票。他们对该股给予了 “跑赢大盘” 的评级。</p>
<p><strong>查看我们最新的 GYRE 股票分析</strong></p>
<h2>Gyre Therapeutics 股价下跌 4.4%</h2>
<p>该公司的 50 日移动平均价格为$11.31，200 日移动平均价格为$12.23。</p>
<p>Gyre Therapeutics（纳斯达克代码：GYRE - 获取免费报告）最近在 3 月 17 日（星期一）发布了季度财报。公司报告每股收益（EPS）为$0.01，低于分析师一致预期的$0.04，差距为$0.03。该季度的收入为 2787 万美元，而一致预期为 2350 万美元。Gyre Therapeutics 的净利润率为-84.57%，股本回报率为-118.43%。</p>
<h2>Gyre Therapeutics 内部活动</h2>
<p>在相关消息中，总裁马松江于 12 月 26 日（星期四）出售了 2000 股公司的股票，交易平均价格为$12.70，总价值为$25,400.00。交易完成后，总裁现在持有 2928467 股公司股票，价值$37,191,530.90。此次交易代表其持股比例下降了 0.07%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。内部人士在上个季度共出售了 36,054 股公司股票，价值$411,597。19.52% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近增加或减少了对该公司的持股。SBI 证券有限公司在第四季度购买了 Gyre Therapeutics 的新头寸，金额约为$1,225,000。FMR LLC 在第三季度购买了 Gyre Therapeutics 的新头寸，金额约为$47,000。Charles Schwab 投资管理公司在第三季度将其在 Gyre Therapeutics 的持股增加了 392.2%。Charles Schwab 投资管理公司现在持有 113,648 股公司股票，价值$1,425,000，此前在上个季度又购买了 90,557 股。State Street Corp 在第三季度将其在 Gyre Therapeutics 的持股增加了 8.8%。State Street Corp 现在持有 104,490 股公司股票，价值$1,310,000，此前在上个季度又购买了 8,412 股。最后，巴克莱 PLC 在第三季度将其在 Gyre Therapeutics 的持股增加了 281.8%。巴克莱 PLC 现在持有 9,288 股公司股票，价值$116,000，此前在上个季度又购买了 6,855 股。机构投资者持有公司 23.99% 的股票。</p>
<h2>Gyre Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Gyre Therapeutics, Inc.是一家生物制药公司，主要专注于 Hydronidone 的开发和商业化，以治疗美国的代谢功能障碍相关性脂肪肝炎。其 Hydronidone 也正在评估用于治疗一系列慢性肝病引起的肝纤维化。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Gyre Therapeutics</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>联邦快递再次对其股价造成重创</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>分析师对火箭实验室保持乐观，底部迹象显现</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>美光股票将在今年重新测试历史高点</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Gyre Therapeutics 吗？</h2>
<p>在考虑 Gyre Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Gyre Therapeutics 并不在名单上。</p>
<p>虽然 Gyre Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GYRE

<p>Gyre Therapeutics (NASDAQ:GYRE) 的股价下跌了 4.7%，至 9.74 美元，交易量较平均水平下降了 40%。该公司报告的季度每股收益为 0.01 美元，未达到预期，但收入为 2787 万美元，超出预期。内部人士最近出售了股票，机构投资者持有 23.99% 的股份。分析师维持 “买入” 评级，但有些人建议有更好的投资选择。该公司专注于开发用于肝病治疗的 Hydronidone</p>

<p>Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares traded down 4.7% on Friday . The stock traded as low as $9.63 and last traded at $9.74. 48,133 shares changed hands during mid-day trading, a decline of 40% from the average session volume of 80,171 shares. The stock had previously closed at $10.22.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc.（纳斯达克代码：GYRE - 获取免费报告）周五股价下跌 4.7%。该股最低交易价为$9.63，最后交易价为$9.74。在午盘交易中，共成交 48,133 股，较平均交易量 80,171 股下降了 40%。该股此前收盘价为$10.22。</p>
</div><p>Get <strong>Gyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, Noble Financial started coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an &#34;outperform&#34; rating on the stock.</p>
<div class="lb-trans"><p>另外，Noble Financial 在 3 月 11 日（星期二）的一份研究报告中开始覆盖 Gyre Therapeutics 的股票。他们对该股给予了 “跑赢大盘” 的评级。</p>
</div><p><strong>View Our Latest Stock Analysis on GYRE</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 GYRE 股票分析</strong></p>
</div><h2>Gyre Therapeutics Stock Down 4.4 %</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 股价下跌 4.4%</h2>
</div><p>The business's 50 day moving average price is $11.31 and its two-hundred day moving average price is $12.23.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为$11.31，200 日移动平均价格为$12.23。</p>
</div><p>Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03). The business had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.</p>
<div class="lb-trans"><p>Gyre Therapeutics（纳斯达克代码：GYRE - 获取免费报告）最近在 3 月 17 日（星期一）发布了季度财报。公司报告每股收益（EPS）为$0.01，低于分析师一致预期的$0.04，差距为$0.03。该季度的收入为 2787 万美元，而一致预期为 2350 万美元。Gyre Therapeutics 的净利润率为-84.57%，股本回报率为-118.43%。</p>
</div><h2>Insider Activity at Gyre Therapeutics</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 内部活动</h2>
</div><p>In related news, President Songjiang Ma sold 2,000 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders sold a total of 36,054 shares of company stock worth $411,597 in the last quarter. 19.52% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，总裁马松江于 12 月 26 日（星期四）出售了 2000 股公司的股票，交易平均价格为$12.70，总价值为$25,400.00。交易完成后，总裁现在持有 2928467 股公司股票，价值$37,191,530.90。此次交易代表其持股比例下降了 0.07%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。内部人士在上个季度共出售了 36,054 股公司股票，价值$411,597。19.52% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. bought a new position in Gyre Therapeutics during the 4th quarter worth approximately $1,225,000. FMR LLC bought a new position in Gyre Therapeutics during the 3rd quarter worth approximately $47,000. Charles Schwab Investment Management Inc. raised its holdings in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after purchasing an additional 90,557 shares during the last quarter. State Street Corp raised its holdings in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after purchasing an additional 8,412 shares during the last quarter. Finally, Barclays PLC raised its holdings in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after purchasing an additional 6,855 shares during the last quarter. Institutional investors own 23.99% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。SBI 证券有限公司在第四季度购买了 Gyre Therapeutics 的新头寸，金额约为$1,225,000。FMR LLC 在第三季度购买了 Gyre Therapeutics 的新头寸，金额约为$47,000。Charles Schwab 投资管理公司在第三季度将其在 Gyre Therapeutics 的持股增加了 392.2%。Charles Schwab 投资管理公司现在持有 113,648 股公司股票，价值$1,425,000，此前在上个季度又购买了 90,557 股。State Street Corp 在第三季度将其在 Gyre Therapeutics 的持股增加了 8.8%。State Street Corp 现在持有 104,490 股公司股票，价值$1,310,000，此前在上个季度又购买了 8,412 股。最后，巴克莱 PLC 在第三季度将其在 Gyre Therapeutics 的持股增加了 281.8%。巴克莱 PLC 现在持有 9,288 股公司股票，价值$116,000，此前在上个季度又购买了 6,855 股。机构投资者持有公司 23.99% 的股票。</p>
</div><h2>Gyre Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc.是一家生物制药公司，主要专注于 Hydronidone 的开发和商业化，以治疗美国的代谢功能障碍相关性脂肪肝炎。其 Hydronidone 也正在评估用于治疗一系列慢性肝病引起的肝纤维化。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Gyre Therapeutics</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>FedEx Delivers Another Crushing Blow to Its Stock Price</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Micron Stock Will Retest All-Time Highs This Year</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Gyre Therapeutics</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>联邦快递再次对其股价造成重创</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>分析师对火箭实验室保持乐观，底部迹象显现</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>美光股票将在今年重新测试历史高点</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Gyre Therapeutics 吗？</h2>
</div><p>Before you consider Gyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Gyre Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Gyre Therapeutics 并不在名单上。</p>
</div><p>While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Gyre Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Gyre Therapeutics (NASDAQ:GYRE) 股价下跌 4.7% - 现在是卖出的时候吗？